Cargando…

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer

AIM OF THE STUDY: Many studies have shown that interferon-α (IFN-α) enhances the antiproliferative effect of gefitinib in some solid tumours. We aimed to determine the effect of combining IFN-α with gefitinib in human non-small cell lung cancer (NSCLC) cell lines (A549, H1299, HCC827) with different...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Chi, Weng, Shanshan, Duan, Yin, Ding, Ling, Zhang, Suzhan, Huang, Jianjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2016
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032161/ https://www.ncbi.nlm.nih.gov/pubmed/27688730 http://dx.doi.org/10.5114/wo.2016.61853

Ejemplares similares

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Estrogen Receptor-α36 Is Involved in Pterostilbene-Induced Apoptosis and Anti-Proliferation in In Vitro and In Vivo Breast Cancer
por: Pan, Chi, et al.
Publicado: (2014)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

PARK2 Suppresses Proliferation and Tumorigenicity in Non-small Cell Lung Cancer
por: Duan, Huijie, et al.
Publicado: (2019)

Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells
por: Li, Jiajin, et al.
Publicado: (2016)

Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
por: Wang, Liang, et al.
Publicado: (2018)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
por: Jian, Hong, et al.
Publicado: (2017)

Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
por: Wang, Hsian-Yu, et al.
Publicado: (2016)

Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer
por: Lu, Xiangdong, et al.
Publicado: (2021)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
por: Cappuzzo, F, et al.
Publicado: (2005)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription
por: Yuan, Weiwei, et al.
Publicado: (2019)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
por: Carotenuto, Pietro, et al.
Publicado: (2011)

Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
por: Yeung, Yiu To, et al.
Publicado: (2018)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
por: Yuan, Ying, et al.
Publicado: (2014)

MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma
por: Ning, Zhi-Qiang, et al.
Publicado: (2016)

The Effects and Mechanisms by which Saikosaponin-D Enhances the Sensitivity of Human Non-small Cell Lung Cancer Cells to Gefitinib
por: Tang, Jian-cai, et al.
Publicado: (2019)

Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16
por: Wang, Ning, et al.
Publicado: (2018)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells
por: Pan, Zhenzhen, et al.
Publicado: (2020)

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro
por: Hu, Yong, et al.
Publicado: (2017)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial
por: Ma, Yuxiang, et al.
Publicado: (2022)

let-7 and miR-17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer
por: Yin, Jun, et al.
Publicado: (2019)

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
por: Yin, Yong-Mei, et al.
Publicado: (2010)

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
por: Nishio, M, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_h30febrr4k7gr7nmfv9lav9gg1